Chemotherapy for AIDS-associated Kaposi's sarcoma

J. Kahn, Donald W Northfelt, P. Volberding

Research output: Contribution to journalArticlepeer-review


Clinical staging and response criteria for AIDS-associated Kaposi's sarcoma (AIDS-KS) are not well-developed, but classifying patients into limited or extensive disease categories allows a clinician to select appropriate local or systemic therapy. A prospective staging system has been proposed to uniformly evaluate pretreatment patient characteristics and subsequent clinical responses. Combination chemotherapy is effective, but its use is often limited by toxicities. Antiretroviral medications, if clinically tolerated, should be continued during combination chemotherapy. Future therapies will evaluate the utility of ddI or ddC with combination chemotherapy. A second area of research involves combintion therapy using chemotherapy and antiretroviral agents along with growth factors to limit myelotoxicity.

Original languageEnglish (US)
Pages (from-to)57-63
Number of pages7
Issue number10
StatePublished - 1991
Externally publishedYes

ASJC Scopus subject areas

  • Oncology


Dive into the research topics of 'Chemotherapy for AIDS-associated Kaposi's sarcoma'. Together they form a unique fingerprint.

Cite this